• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与健康对照相比,肠易激综合征患者肠道微生物群分子特征的改变:一项系统评价和荟萃分析。

Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis.

作者信息

Liu Hai-Ning, Wu Hao, Chen Yu-Zhuo, Chen Yan-Jie, Shen Xi-Zhong, Liu Tao-Tao

机构信息

Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai, China.

Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai, China.

出版信息

Dig Liver Dis. 2017 Apr;49(4):331-337. doi: 10.1016/j.dld.2017.01.142. Epub 2017 Jan 21.

DOI:10.1016/j.dld.2017.01.142
PMID:28179092
Abstract

BACKGROUND

Many studies have reported significant changes in intestinal microbiota in irritable bowel syndrome (IBS) patients based on quantitative real-time PCR analysis.

AIMS

We aimed to review the alterations in intestinal microbiota.

METHODS

An online search up to June 9, 2016, was conducted. This systematic review and meta-analysis included differential expression of intestinal microbiota in patients with IBS versus healthy controls (HCs) and subgroup analysis. We assessed the quality of the included studies using an original assessment tool.

RESULTS

A total of 13 articles involving 360 IBS patients and 268 healthy controls were included. The quality assessment scores for these articles ranged from 5 to 8. Significant differences in expression in IBS patients were observed for Lactobacillus (SMD=-0.85, P<0.001, I=28%), Bifidobacterium (SMD=-1.17, P<0.001, I=79.3%), and Faecalibacterium prausnitzii (SMD=-1.05, P<0.001, I=0.0%) but not Bacteroides-Prevotella group, Escherichia coli or other genera or species. Subgroup analysis showed that diarrhea-predominant IBS patients had significantly different expression of Lactobacillus (SMD=-1.81, P<0.001) and Bifidobacterium (SMD=-1.45, P<0.001).

CONCLUSION

Down-regulation of bacterial colonization including Lactobacillus, Bifidobacterium and F. prausnitzii was observed in IBS patients, particularly in diarrhea-predominant IBS (IBS-D). Microbiota changes participate in the pathogenesis of IBS and may underlie the efficacy of probiotic supplements.

摘要

背景

许多研究报告称,基于定量实时聚合酶链反应分析,肠易激综合征(IBS)患者的肠道微生物群有显著变化。

目的

我们旨在综述肠道微生物群的改变。

方法

进行了截至2016年6月9日的在线搜索。这项系统评价和荟萃分析包括IBS患者与健康对照(HCs)肠道微生物群的差异表达及亚组分析。我们使用一种原创评估工具评估纳入研究的质量。

结果

共纳入13篇文章,涉及360例IBS患者和268例健康对照。这些文章的质量评估分数在5至8分之间。IBS患者中,乳酸杆菌(标准化均数差=-0.85,P<0.001,I=28%)、双歧杆菌(标准化均数差=-1.17,P<0.001,I=79.3%)和普拉梭菌(标准化均数差=-1.05,P<0.001,I=0.0%)的表达存在显著差异,但拟杆菌-普雷沃菌属、大肠杆菌或其他属或种无显著差异。亚组分析显示,腹泻型IBS患者的乳酸杆菌(标准化均数差=-1.81,P<0.001)和双歧杆菌(标准化均数差=-1.45,P<0.001)表达有显著差异。

结论

IBS患者中观察到包括乳酸杆菌、双歧杆菌和普拉梭菌在内的细菌定植下调,尤其是在腹泻型IBS(IBS-D)中。微生物群变化参与IBS的发病机制,可能是益生菌补充剂疗效的基础。

相似文献

1
Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis.与健康对照相比,肠易激综合征患者肠道微生物群分子特征的改变:一项系统评价和荟萃分析。
Dig Liver Dis. 2017 Apr;49(4):331-337. doi: 10.1016/j.dld.2017.01.142. Epub 2017 Jan 21.
2
Physical activity for treatment of irritable bowel syndrome.体力活动治疗肠易激综合征。
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD011497. doi: 10.1002/14651858.CD011497.pub2.
3
Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis.肠易激综合征患者肠道微生物群的改变:一项系统评价和荟萃分析。
J Gastroenterol Hepatol. 2017 Jan;32(1):28-38. doi: 10.1111/jgh.13471.
4
Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.益生菌治疗肠易激综合征的疗效:一项系统评价和网状Meta分析
Front Cell Infect Microbiol. 2022 Apr 1;12:859967. doi: 10.3389/fcimb.2022.859967. eCollection 2022.
5
Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels.肠易激综合征中的白细胞介素 6:白细胞介素 6(-G174C)和循环白细胞介素 6 水平的系统评价和荟萃分析。
Cytokine. 2017 Nov;99:132-138. doi: 10.1016/j.cyto.2017.08.017. Epub 2017 Sep 5.
6
Dietary interventions for recurrent abdominal pain in childhood.儿童复发性腹痛的饮食干预措施
Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD010972. doi: 10.1002/14651858.CD010972.pub2.
7
Probiotics therapy for adults with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of 10 RCTs.益生菌治疗成人腹泻型肠易激综合征:10 项 RCT 的系统评价和荟萃分析。
Int J Colorectal Dis. 2022 Nov;37(11):2263-2276. doi: 10.1007/s00384-022-04261-0. Epub 2022 Oct 17.
8
The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.益生菌、益生元、合生菌和粪便微生物群移植治疗肠易激综合征的疗效:系统评价和网络荟萃分析。
Nutrients. 2024 Jul 2;16(13):2114. doi: 10.3390/nu16132114.
9
Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.不同益生菌菌株和混合物在肠易激综合征中的疗效特异性:系统评价和网络荟萃分析。
Nutrients. 2023 Sep 4;15(17):3856. doi: 10.3390/nu15173856.
10
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.婴儿双歧杆菌35624对肠易激综合征患者的疗效:一项荟萃分析。
Curr Med Res Opin. 2017 Jul;33(7):1191-1197. doi: 10.1080/03007995.2017.1292230. Epub 2017 Mar 7.

引用本文的文献

1
Randomised controlled trial: nutritional supplements to relieve irritable bowel syndrome symptoms by targeting the gut microbiota.随机对照试验:通过针对肠道微生物群缓解肠易激综合征症状的营养补充剂
J Nutr Sci. 2025 Jul 11;14:e46. doi: 10.1017/jns.2025.10021. eCollection 2025.
2
The Relationship Between Prematurity and Mode of Delivery with Disorders of Gut-Brain Interaction in Children.儿童早产及分娩方式与肠-脑互动障碍的关系
Children (Basel). 2025 Jun 18;12(6):799. doi: 10.3390/children12060799.
3
Therapeutic Potential of Flavonoids and Flavonoid-Rich Compounds in Irritable Bowel Syndrome.
黄酮类化合物及富含黄酮类化合物的复合物在肠易激综合征中的治疗潜力
Drug Des Devel Ther. 2025 Jun 6;19:4895-4910. doi: 10.2147/DDDT.S515004. eCollection 2025.
4
Menthacarin, a proprietary combination of peppermint and caraway oil, alters cultured human fecal microbiota composition, resulting in increased SCFA production.门塔卡林是薄荷油和葛缕子油的专利组合,它会改变培养的人类粪便微生物群的组成,从而增加短链脂肪酸的产生。
Front Pharmacol. 2025 Apr 30;16:1569052. doi: 10.3389/fphar.2025.1569052. eCollection 2025.
5
The Role of the Nurse in the Management of Irritable Bowel Syndrome: A Narrative Review.护士在肠易激综合征管理中的作用:一项叙述性综述
Transl Med UniSa. 2023 Dec 22;25(1):28-37. doi: 10.37825/2239-9747.1043. eCollection 2023.
6
Periodic Changes in the Gut Microbiome in Women with the Mixed Type of Irritable Bowel Syndrome.混合型肠易激综合征女性肠道微生物群的周期性变化
Biomedicines. 2025 Mar 7;13(3):652. doi: 10.3390/biomedicines13030652.
7
in Pediatric Irritable Bowel Syndrome: A Multicentric, Randomized, Double-Blind, Placebo-Controlled Trial.在小儿肠易激综合征:一项多中心、随机、双盲、安慰剂对照试验中。
Microorganisms. 2025 Mar 10;13(3):627. doi: 10.3390/microorganisms13030627.
8
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.肠道菌群失调相关疾病的粪便微生物群移植研究进展
Adv Sci (Weinh). 2025 Apr;12(13):e2413197. doi: 10.1002/advs.202413197. Epub 2025 Feb 27.
9
Risk factors for developing irritable bowel syndrome: systematic umbrella review of reviews.肠易激综合征的发病风险因素:系统性综述的综合评价
BMC Med. 2025 Feb 21;23(1):103. doi: 10.1186/s12916-025-03930-5.
10
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study.微囊化丁酸钠、益生菌和低聚果糖混合物治疗肠易激综合征患者的疗效和安全性——一项随机、双盲、安慰剂对照研究
J Clin Med. 2024 Dec 24;14(1):6. doi: 10.3390/jcm14010006.